Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings data on Monday. The company reported ($3.82) EPS for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52), Zacks reports. The company had revenue of $44.04 million during the quarter, compared to analysts’ expectations of $39.56 million. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Trading Down 6.9%

NASDAQ:KPTI traded down $0.42 during trading hours on Tuesday, hitting $5.65. 190,552 shares of the stock traded hands, compared to its average volume of 142,289. The firm has a 50 day moving average price of $6.36 and a 200 day moving average price of $5.40. The firm has a market cap of $48.99 million, a price-to-earnings ratio of -0.39 and a beta of 0.35. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $14.24.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the business. Bridgeway Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the second quarter worth $163,000. Bank of America Corp DE lifted its holdings in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $45,000. Finally, XTX Topco Ltd acquired a new position in Karyopharm Therapeutics in the second quarter worth approximately $56,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KPTI has been the subject of several analyst reports. Royal Bank Of Canada reduced their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright upgraded shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Monday, October 13th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday, October 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, October 8th. Finally, Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).